COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in de Novo Coronary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent (IN-PACT CORO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01057563
Recruitment Status : Unknown
Verified January 2010 by Catholic University of the Sacred Heart.
Recruitment status was:  Recruiting
First Posted : January 27, 2010
Last Update Posted : January 27, 2010
Information provided by:
Catholic University of the Sacred Heart

Brief Summary:

Restenosis due to neointimal hyperplasia causes repeat target vessel revascularization in a relevant number of patients undergoing percutaneous coronary interventions (PCI). Drug-eluting stents (DES) are currently adopted to reduce the rate of restenosis; however, they may increase risk of stent thrombosis.

Experimental data and first clinical experiences showed that inhibition of neointimal hyperplasia may be obtained by local administration of anti-proliferative drugs (like paclitaxel) loaded on the surface of angioplasty balloons. Data on the efficacy of novel coronary drug-eluting balloons (DEBs) are lacking.

Aims of this open label prospective, randomized trial is to evaluate neointimal hyperplasia in patients undergoing bare-metal stent (BMS) implantation alone compared to those receiving additional DEB use and to assess if the technique of DEB use may affect the degree of neointimal hyperplasia.

Neointimal hyperplasia will be assessed by Optical coherence tomography (OCT).

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: drug (paclitaxel)-eluting balloon (DEB) Device: bare-metal stent (BMS) Device: Drug (paclitaxel)-eluting balloon (DEB) Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: IN-PACT CORO INtimal hyPerplasia evAluated by oCT in de Novo COROnary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent
Study Start Date : November 2009
Estimated Primary Completion Date : November 2010

Arm Intervention/treatment
Active Comparator: BMS group
Patients undergoing PCI with BMS implantation
Device: bare-metal stent (BMS)
BMS implantation

Active Comparator: PRE-DEB group
Patients undergoing PCI with BMS implantation after lesion predilation with DEB
Device: drug (paclitaxel)-eluting balloon (DEB)
BMS implantation after lesion predilation with DEB

Active Comparator: POST-DEB group
Patients undergoing PCI with BMS implantation followed by postdilation with DEB
Device: Drug (paclitaxel)-eluting balloon (DEB)
BMS implantation followed by post-dilation with DEB

Primary Outcome Measures :
  1. Primary Endpoint: Neo-intimal area (mm²). [ Time Frame: 6 months post procedure ]

Secondary Outcome Measures :
  1. Secondary Endpoints: - 6m percentage of uncovered struts. - 6m percentage of struts with ISA. - 6m percentage of protruding struts. [ Time Frame: 6 months post procedure ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both (female sex with child-bearing potential excluded) Accepts Healthy Volunteers: No

Inclusion Criteria:

  • Non-diabetic patients with a stable coronary artery disease, undergoing elective PCI with BMS
  • de novo non-complex lesions (no bifurcation lesions, no chronic total occlusions, no severe calcifications, no moderate-to-severe tortuosities) located in straight coronary segments.
  • lesion length ≥10 mm and <25 mm.
  • vessel size requiring a single stent with diameter between 3.0 and 3.5mm.

Exclusion Criteria:


  • age <18 years or impossibility to give informed consent,
  • diabetes mellitus
  • female sex with child-bearing potential,
  • life expectancy less than 6 months or any condition impeding clinical follow-up (no fixed address, etc),
  • significant platelet count alteration (<100,000 cells/mm3 or > 700,000 cells/mm3),
  • gastrointestinal bleeding requiring surgery or blood transfusions within 4 previous weeks,
  • participation to another study with any investigational device or drug within which is still in the active phase.
  • history of clotting pathology, known hypersensitivity to aspirin, heparin, cobalt- chromium, paclitaxel, contrast dye,
  • renal failure with creatinine value > 2.5 mg/dl,
  • poor cardiac function as defined by left ventricular global ejection fraction ≤ 30%
  • acute myocardial infarction within the past 48 hours.
  • non ST-elevation acute coronary syndrome


  • left main coronary artery disease,
  • lesions in coronary artery bypass grafts,
  • no suitable anatomy for OCT scan
  • bifurcation lesions, chronic total occlusions, severe calcifications, moderate-to-severe tortuosities
  • presence of additional non target lesions requiring treatment, within and outside the target vessel, which are not successfully treated (non target lesions must be treated prior to the target lesion)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01057563

Layout table for location contacts
Contact: Francesco Burzotta, MD, PhD 39-349-4295290

Layout table for location information
Institute of Cardiology, Catholic University of Sacred Heart Recruiting
Rome, Italy, 00168
Contact: Francesco Burzotta, MD, PhD    39-349-4295290   
Sponsors and Collaborators
Catholic University of the Sacred Heart
Layout table for investigator information
Principal Investigator: Francesco Burzotta, MD, PhD Catholic University of Sacred Heart
7. Tatsuya I, Mitsuyasu T, Yoshihiro T. Optical coherence tomography analysis of neointimal stent coverage in sirolimus eluting stents compared with bare metal stents. American College of Cardiology Scientific Sessions 2006. J Am Coll Cardiol 2006;47 Suppl:A2906-73

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Francesco Burzotta, MD, PhD, Catholic University of Sacred Heart Identifier: NCT01057563    
Other Study ID Numbers: A/582/CE/2009
First Posted: January 27, 2010    Key Record Dates
Last Update Posted: January 27, 2010
Last Verified: January 2010
Keywords provided by Catholic University of the Sacred Heart:
Coronary artery disease
Neointimal hyperplasia
Drug-eluting balloon
Optical coherence tomography
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Pathologic Processes
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action